Delivery of ATRA and Gefitinib by Polyphenylalanine Nanosystem to Overcome EGFR-TKI Resistance in Lung Adenocarcinoma

被引：0
|
作者：
Liu, S. [1 ]
Zhou, H. [2 ]
Xu, B. [1 ]
Deng, J. [1 ]
Zeng, F. [2 ]
Qiu, H. [2 ]
机构：
[1] Southern Med Univ, Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Thorac Surg, Guangzhou, Peoples R China
[2] Southern Med Univ, Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Gen Practice, Guangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Polyphenylalanine; EGFR-TKI resistance; Non-small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.08-04
引用
收藏
页码：S198 / S198
页数：1
相关论文
共 50 条
  • [41] Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance —A Multicenter Randomized Trial
    Ping Fang
    Liqin Zhang
    Xianru Zhang
    Jiawen Yu
    Jun Sun
    Qi-an Jiang
    Mingbao Zha
    Anastasia P. Nesterova
    Hongbao Cao
    Scientific Reports, 9
  • [42] Progesterone receptor membrane component 1 is a candidate key molecule involved EGFR-TKI resistance in lung adenocarcinoma
    Lin, Ying
    Higashisaka, Kazuma
    Hanamuro, Sachiyo
    Izusawa, Kohei
    Konishi, Hiroto
    Haga, Yuya
    Yang, Lili
    Tsujino, Hirofumi
    Nagano, Kazuya
    Tsutsumi, Yasuo
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [43] SUCCESSFUL TREATMENT OF SWITCHING EGFR-TKI FOR ADVANCED LUNG ADENOCARCINOMA BECAUSE OF INTERSTITIAL LUNG DISEASE
    Zeng, Xianghua
    CHEST, 2024, 166 (04) : 4125A - 4126A
  • [44] Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance - A Multicenter Randomized Trial
    Fang, Ping
    Zhang, Liqin
    Zhang, Xianru
    Yu, Jiawen
    Sun, Jun
    Jiang, Qi-an
    Zha, Mingbao
    Nesterova, Anastasia P.
    Cao, Hongbao
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [45] Mechanism of resistance to third-generation EGFR-TKI, osimertinib, in lung adenocarcinoma PC-9 cells
    Yamaoka, Toshimitsu
    Kishino, Yasunari
    Kusumoto, Sojiro
    Ando, Koichi
    Ohmori, Tohru
    Sagara, Hironori
    Tsurutani, Junji
    CANCER SCIENCE, 2022, 113 : 1633 - 1633
  • [46] Biomarkers of lung cancer response to EGFR-TKI
    Johnson, B.
    EJC SUPPLEMENTS, 2007, 5 (08): : 14 - 15
  • [47] Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma
    Zhang, Yanwei
    Jin, Bo
    Shao, Minhua
    Dong, Yu
    Lou, Yuqing
    Huang, Aimi
    Han, Baohui
    TUMOR BIOLOGY, 2014, 35 (05) : 4921 - 4928
  • [48] EGFR-TKI Alone or with Concomitant Radiotherapy for Brain Metastases in Lung Adenocarcinoma Patients with EGFR Gene Mutations
    Chen, Yongshun
    Yang, Jing
    Li, Xue
    Hao, Daxuan
    Wu, Xiaoyuan
    Yang, Yuanyuan
    Hu, Xiaona
    He, Chunyu
    Wang, Wen
    Liu, Jinsong
    Wang, Jianhua
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S278 - S278
  • [49] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated)
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S873 - S873
  • [50] Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
    Tamiya, Motohiro
    Tamiya, Akihiro
    Suzuki, Hidekazu
    Moriizumi, Kazunori
    Nakahama, Kenji
    Taniguchi, Yoshihiko
    Kunimasa, Kei
    Kimura, Madoka
    Inoue, Takako
    Kuhara, Hanako
    Nishino, Kazumi
    Hirashima, Tomonori
    Atagi, Shinji
    Imamura, Fumio
    Kumagai, Toru
    ANTICANCER RESEARCH, 2019, 39 (07) : 3923 - 3929
12345